LDOS — Leidos Holdings, Inc.

The tape and the fundamentals disagree, which is why sentiment reads genuinely neutral rather than bullish or bearish. On 2026-08-04 Leidos beat Q2 consensus EPS by roughly 12% ($3.26 non-GAAP vs ~$2.91 expected), posted record operating cash flow of $793M and $761M of free cash flow, and raised FY26 revenue, EPS and cash-flow guidance. Yet as of 2026-09-13 the stock is down 8.21% over the past month and 25.88% over six months, even as positive late-August/September news landed (a Naval Health Research Center behavioral health award, expanded DoD cyber operations, Sea Hunter at RIMPAC and Seahawk with the Theodore Roosevelt CSG). Sell-side is more constructive than the tape: 17 Buy / 11 Hold, consensus target $152.75, recent-average target $144.40, with Citigroup at $161 (Buy) and Jefferies at $145 (Hold). The market is pricing margin and federal-budget skepticism, not the guidance raise - and the 2026-09-13 RSI of 43.5 confirms neither panic nor enthusiasm.

Revenue has quietly reaccelerated over this 12-quarter window: $3.92B (Sep-23) -> $3.98B -> $3.98B -> $4.13B -> $4.19B -> $4.37B -> $4.25B -> $4.25B -> $4.47B -> $4.21B -> $4.40B -> $4.56B (Q2'26). YoY growth moved from just +2.9% in Q2'25 to +7.2% in Q2'26, the best print in the window. Margins are the problem, not the top line: GAAP operating margin peaked at 13.4% in Q2'25 and has since printed 12.0%, 11.2%, 11.5% and 11.1% - four consecutive quarters below the prior-year peak, with Q2'26's 11.1% down about 230bps YoY. GAAP diluted EPS has been under $3.00 for four straight quarters ($3.01 -> $2.82 -> $2.53 -> $2.56 -> $2.81) and actually fell year-over-year in Q2'26. Cash generation is the genuine inflection: TTM free cash flow of $2.16B is up roughly 64% from $1.32B a year earlier, and management cut FY26 capex guidance to about $250M. Net read: revenue accelerating, GAAP margins structurally softer, cash conversion sharply better - and note the Q2 'beat' leaned on roughly $0.45/share of non-GAAP adjustments (GAAP $2.81 vs non-GAAP $3.26).

Cheap on cash flow, only fair on earnings quality - which is the honest tension here. As of 2026-09-13 the trailing P/E was 11.92 against a 5-year average of 28.88, P/S was 0.919 vs a 5-year average of 1.09, EV/EBITDA was 9.7x, and the TTM FCF yield was about 13.3% ($2.16B FCF / $16.2B market cap). Forward P/E is ~10.4x on both the FY26 guidance midpoint ($12.35) and FY27 consensus ($12.385), meaning the market is paying essentially nothing for growth. The PEG of 9.79 is a data artifact built off a near-flat trailing growth rate and should be ignored. The discount to the 5-year P/E average is exaggerated by depressed 2021-22 earnings comps; measured against the more realistic mid-teens to low-20s multiples LDOS carried in 2023-2024, this is still a meaningful de-rating. Cheap versus its own history - but the margin trend is the reason, and the multiple will not normalise until GAAP operating margin stops sliding.

At roughly 10.4x forward EPS, the stock is priced for near-zero FY27 EPS growth (consensus $12.385 vs FY26 guidance midpoint $12.35), which looks too pessimistic against 7.2% Q2 revenue growth, a 2.2x book-to-bill in the Defense segment, and record cash flow - but the pessimism is not irrational. Q2'26 GAAP EPS of $2.81 fell from $3.01 a year earlier, so the headline beat was an adjusted-number story, and operating margin has compressed for four straight quarters. Watch the GAAP/non-GAAP gap and the margin line, not the headline beat. If the 2026-11-03 Q3 print shows operating margin stabilising near 11-12% with revenue holding +6-7%, the multiple has room to re-rate toward 12-13x; another sub-11% margin quarter and the market will keep treating the low multiple as deserved. One unresolved item the news flow does not explain: total assets jumped from $13.49B (period ending 2026-01-02) to $15.63B (2026-07-03) while long-term debt rose from $5.22B to $6.01B - an un-narrated ~$2.1B balance-sheet expansion that needs clarifying at Q3.

As of 2026-09-13 the chart was neutral-to-soft, not washed out. RSI(14) was 43.5 - neither oversold nor overbought. Price at $128.86 sat 6.08% below the 20-day SMA (approximately $137), 2.98% above the 50-day (approximately $125) and 15.21% below the 200-day (approximately $152), i.e. a bottoming range between roughly $125 and $137 with the long-term downtrend still intact. Returns as of that date: +5.48% over 3 months, -8.21% over 1 month, -25.88% over 6 months. Implication: risk/reward favours scaling in on weakness toward the 50-day near $125 rather than chasing here; a weekly close back above the 200-day at ~$152 would be the first real confirmation of a trend change - and it coincidentally matches the analyst consensus target.

• Federal budget and appropriations risk: Leidos' revenue is overwhelmingly U.S. government (DoD, intelligence community, civil and health agencies), so a continuing resolution, spending cap or program re-phasing directly delays awards and revenue recognition.
• Geopolitical demand tailwind: Indo-Pacific naval activity and Middle East tensions are underpinning demand for maritime autonomy (Sea Hunter, Seahawk), cyber defence and ISR - the highest-multiple part of the defence narrative.
• Rates and leverage: about $6.0B of long-term debt against 1.245 debt/equity means interest expense and refinancing costs matter; a stabilising or easing rate environment makes the ~13% FCF yield relatively more attractive.
• Defence-tech sector rotation: autonomy and AI themes have re-rated parts of the sector, but LDOS' 0.57 beta means it captures less of a risk-on rally while offering a real cushion in drawdowns.
• Health-segment policy drag: the suspension of certain VA exam incentives and prior Defense Health Agency contract losses continue to weigh on Managed Health even as the Defence segment accelerates - a genuine intra-company divergence.

• Q3 2026 results on 2026-11-03 (consensus EPS approximately $3.12) - the single biggest test of whether Q2's revenue acceleration and the raised FY26 guidance hold, and whether GAAP operating margin stabilises.
• Conversion of the Defense segment's 2.2x Q2 book-to-bill into FY27 revenue - bookings are the leading indicator that every trailing metric in this dataset structurally cannot see.
• Maritime autonomy momentum (Sea Hunter at RIMPAC, Seahawk with the Theodore Roosevelt Carrier Strike Group) as a potential multiple-expansion narrative in an otherwise low-multiple services name.
• Capital return: the $0.43/share quarterly dividend payable 2026-09-30, plus any buyback acceleration funded by a ~13% free-cash-flow yield.
• Clarification of the H1 2026 balance-sheet expansion (~$2.1B more total assets and ~$1.4B more gross long-term debt versus the period ending 2026-01-02) - if that reflects a debt-funded acquisition, the accretion and integration detail becomes a swing factor.

• GAAP margin compression: operating margin fell from 13.4% (Q2'25) to 11.1% (Q2'26), four straight quarters below the prior-year peak. If this is contract mix and re-compete pricing rather than timing, the low multiple is deserved, not a discount.
• Earnings-quality gap: Q2'26 GAAP EPS of $2.81 was below Q2'25's $3.01 while the non-GAAP number beat at $3.26 - roughly $0.45/share of adjustments. The beat-and-raise story is an adjusted-earnings story.
• Customer concentration and procurement risk: heavy dependence on U.S. federal budgets, plus contract protests, recompetes and the Defense Health Agency contract losses already seen in 2026.
• Rising leverage: long-term debt up from $4.63B (period ending 2025-10-03) to $6.01B (2026-07-03) with only $748M of cash - little cushion for a large debt-funded deal combined with a budget shock.
• Fixed-price contract execution risk and the Health segment drag from the VA exam incentive suspension, either of which could offset Defence momentum in a given quarter.

Leidos is a cash machine trading at a genuinely discounted price - roughly 10.4x forward EPS, 9.7x EV/EBITDA and a ~13% TTM free-cash-flow yield on a 0.57-beta government services franchise - with revenue reaccelerating to +7% and a 2.2x Defense book-to-bill. But the discount is not free money: GAAP operating margin has compressed about 230bps year-over-year, GAAP EPS actually fell in Q2, so the 2026 'beat' rests on adjusted numbers, and the balance sheet grew ~$2.1B in H1 2026 without explanation in the news flow. Cheap enough to own for the cash flow, not yet clean enough to call a re-rating candidate - I would want margin stabilisation confirmed at Q3 on 2026-11-03 before getting aggressive.

Blended three approaches using data as of 2026-09-13: (1) 12.0x FY2027 consensus EPS of $12.385 = ~$149 - a multiple below LDOS' 2023-2024 mid-teens-to-low-20s range to reflect persistent margin compression, but well above the then-current ~10.4x; (2) normalised free cash flow of ~$1.85B (haircut from the record $2.16B TTM to assume working-capital normalisation) capitalised at a 10% target FCF yield = ~$147/share; (3) 10.5x FY26E EBITDA of ~$2.28B, less $5.26B of net debt (long-term debt $6.01B minus $748M cash), = ~$148/share. The three methods cluster at $147-$149, so I use $148 - about 15% above the 2026-09-13 price of $128.86, below the $152.75 analyst consensus target, and consistent with the deterministic score's 'Cheap vs. its own history' valuation signal.